Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aura Biosciences (AURA) EBITDA (2020 - 2026)

Aura Biosciences filings provide 7 years of EBITDA readings, the most recent being -$33.8 million for Q1 2026.

  • Quarterly EBITDA fell 22.25% to -$33.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$112.7 million through Mar 2026, down 19.13% year-over-year, with the annual reading at -$106.6 million for FY2025, 22.2% down from the prior year.
  • EBITDA hit -$33.8 million in Q1 2026 for Aura Biosciences, down from -$25.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$12.8 million in Q1 2022 and bottomed at -$33.8 million in Q1 2026.
  • Average EBITDA over 5 years is -$21.3 million, with a median of -$20.3 million recorded in 2024.
  • The largest annual shift saw EBITDA crashed 80.13% in 2022 before it grew 1.71% in 2025.
  • Aura Biosciences' EBITDA stood at -$16.5 million in 2022, then tumbled by 30.17% to -$21.5 million in 2023, then dropped by 22.0% to -$26.2 million in 2024, then grew by 1.71% to -$25.7 million in 2025, then crashed by 31.33% to -$33.8 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's EBITDA are -$33.8 million (Q1 2026), -$25.7 million (Q4 2025), and -$26.1 million (Q3 2025).